{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:18Z","timestamp":1787026998734,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Doxorubicin (DOX) is a primary treatment for breast cancer (BC), but its widespread use is hindered by cardiotoxicity. Pegylated liposomal doxorubicin (PLD) has been developed to enhance the efficacy of DOX and mitigate its cardiotoxic effects. However, PLD is associated with adverse reactions (ADRs) such as hand-foot syndrome (HFS) and oral mucositis (OM), which have garnered significant attention. Although not life-threatening, HFS and OM can cause severe discomfort and functional impairment. Severe cases may necessitate a reduced PLD dose or even delay or interrupt chemotherapy, ultimately leading to decreased medication compliance. Here, we conduct an analysis of the risk factors associated with HFS and OM during the PLD chemotherapy regimen, thus providing early warning indicators for the potential occurrence of these adverse reactions in BC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, a total of 395 BC patients receiving PLD chemotherapy were enrolled. Follow-up observations towards the baseline and clinical characteristics in these patients were exhibited. The evaluation of HFS and OM in these patients was also performed based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Analysis of factors influencing simultaneous incidence of HFS and OM was executed using the univariate analysis and multivariate logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dose intensity, history of cholelithiasis, ALT, AST, and Hb were identified as related risk factors for HFS. Dose intensity and reductions in white blood cell (WBC) counts were associated with the risk of OM. Furthermore, increased dose intensity, decreased WBC counts, and a history of cholelithiasis emerged as independent risk factors for the concurrent occurrence of HFS and OM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study investigated the various risk factors related to HFS, OM, and their combination in BC patients undergoing PLD chemotherapy, offering insights for the prevention and treatment of BC and other cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1564681","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:14:08Z","timestamp":1747872848000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin"],"prefix":"10.3389","volume":"15","author":[{"given":"Xianghua","family":"Quan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br J Radio"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0459","article-title":"Breast cancer: presentation, investigation and management","volume":"83","author":"Katsura","year":"2022","journal-title":"Br J Hosp Med (Lond)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082286","article-title":"Racial disparity in anthracycline-induced cardiotoxicity in breast cancer patients","volume":"11","author":"Balaji","year":"2023","journal-title":"Biomedicines"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1049\/nbt2.12094","article-title":"The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumor activity","volume":"16","author":"Dadpour","year":"2022","journal-title":"IET Nanobiotechnol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2020.1746886","article-title":"Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer","volume":"32","author":"Yao","year":"2020","journal-title":"J Chemother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2008.0490","article-title":"Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome","volume":"18","author":"Mangana","year":"2008","journal-title":"Eur J Dermat ol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts","volume":"44","author":"von Moos","year":"2008","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl477","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot\u2019 syndrome)","volume":"18","author":"Lorusso","year":"2007","journal-title":"Ann Onco"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2017.9","article-title":"The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials","volume":"24","author":"Ansari","year":"2017","journal-title":"Cancer Gene The"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000795","article-title":"Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing","volume":"30","author":"Rose","year":"2019","journal-title":"AnticancerDrugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06199-5","article-title":"Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy","volume":"29","author":"Curra","year":"2021","journal-title":"Support Care Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13046-020-01715-7","article-title":"Oral mucositis: the hidden side of cancer therapy","volume":"39","author":"Pulito","year":"2020","journal-title":"J Exp Clin Cancer Re"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2018.30.70.14741","article-title":"Docetaxel induced severe palmar plantar erythro dysesthesia","volume":"30","author":"Kharmoum","year":"2018","journal-title":"Pan Afr Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jog.13334","article-title":"Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"43","author":"Yamada","year":"2017","journal-title":"J Obstet Gynecol Re"},{"key":"B16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12885-021-08028-8","article-title":"Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters","volume":"21","author":"Liang","year":"2021","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.25270\/wnds\/2021.136138","article-title":"Managing oral mucositis in patients with cancer","volume":"33","author":"Bolton","year":"2021","journal-title":"Wounds"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000037","article-title":"Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer","volume":"25","author":"Rom","year":"2014","journal-title":"Anticancer Drug"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2165\/11207510-000000000-00000","article-title":"Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi\u2019s sarcoma","volume":"71","author":"Duggan","year":"2011","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40360-021-00529-3","article-title":"High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study","volume":"22","author":"Zhao","year":"2021","journal-title":"BMC Pharmacol Toxico"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.8.3.331","article-title":"Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer","volume":"8","author":"Minisini","year":"2008","journal-title":"Expert Rev Anticancer The"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.09.031","article-title":"Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients","volume":"131","author":"Ko","year":"2013","journal-title":"Gynecol Onco"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.01.031","article-title":"Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin","volume":"103","author":"Gordinier","year":"2006","journal-title":"Gynecol Onco"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2875-8","article-title":"Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters","volume":"76","author":"Ajgal","year":"2015","journal-title":"Cancer Chemother Pharmaco"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S280187","article-title":"Reactive oxygen species-mediated inflammation and apoptosis in hand-foot syndrome induced by PEGylated liposomal doxorubicin","volume":"16","author":"Hu","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","article-title":"Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin","volume":"26","author":"Yokomichi","year":"2013","journal-title":"Hum Cel"},{"key":"B29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00280-011-1664-2","article-title":"Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients","volume":"69","author":"La-Beck","year":"2012","journal-title":"Cancer Chemother Pharmaco"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.04.007","article-title":"Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer","volume":"114","author":"Tanyi","year":"2009","journal-title":"Gynecol Onco"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000445866","article-title":"Hemoglobin value is the most important factor in the development of hand-foot syndrome under the capecitabine regimen","volume":"62","author":"Naito","year":"2017","journal-title":"Chemotherapy"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.185","article-title":"Interaction between capecitabine and brivudin in a patient with breast cancer","volume":"7","author":"Baena-Ca\u00f1ada","year":"2010","journal-title":"Nat Rev Clin Onco"},{"key":"B33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12905-025-03628-z","article-title":"Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Womens Healt"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1049-y","article-title":"Sequential administration of dose-dense epirubicin\/cyclophosphamide followed by docetaxel\/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer","volume":"65","author":"Nieto","year":"2010","journal-title":"Cancer Chemother Pharmaco"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0126","article-title":"The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials","volume":"18","author":"Gibson","year":"2013","journal-title":"Oncologist"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0605-6","article-title":"Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age","volume":"62","author":"Addeo","year":"2008","journal-title":"Cancer Chemother Pharmaco"},{"key":"B37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000272119","article-title":"Phase II evaluation of liposomal doxorubicin with docetaxel in patients with metastatic breast cancer","volume":"5","author":"Fasano","year":"2010","journal-title":"Breast Care (Basel"},{"key":"B38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13048-021-00790-4","article-title":"The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials","volume":"14","author":"Li","year":"2021","journal-title":"J Ovarian Re"},{"key":"B39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40168-019-0679-5","article-title":"Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis","volume":"7","author":"Hong","year":"2019","journal-title":"Microbiome"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgz012","article-title":"Oral mucosal injury caused by targeted cancer therapies","volume":"2019","author":"Carrozzo","year":"2019","journal-title":"J Natl Cancer Inst Monog"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00652","article-title":"Management of cancer therapy-associated oral mucositis","volume":"16","author":"Brown","year":"2020","journal-title":"JCO Oncol Prac"},{"key":"B42","doi-asserted-by":"publisher","first-page":"bcr2014204056","DOI":"10.1136\/bcr-2014-204056","article-title":"Oral squamous cell carcinoma in a patient treated with long-term pegylated liposomal doxorubicin for recurrent ovarian cancer","volume":"2015","author":"Pezzoli","year":"2015","journal-title":"BMJ Case Re"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1159\/000370343","article-title":"Influence of mechanical stress on palmoplantar erythrodysesthesia\u2013a case report","volume":"38","author":"Jung","year":"2015","journal-title":"Oncol Res Trea"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4054-z","article-title":"Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomaldoxorubicin in ovarian cancer","volume":"26","author":"Bun","year":"2018","journal-title":"Supportive Care Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0923-7534(20)30678-5","article-title":"Mouth cooling to prevent doxorubicin-induced stomatitis","volume":"2","author":"Twelves","year":"1991","journal-title":"Ann Onco"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3290\/j.ohpd.a41659","article-title":"Behavior and prevention of 5\u2019Fluorouracil and doxorubicin-induced oral mucositis in immunocompetent patients with solid tumors: A randomized trial","volume":"16","author":"Rozza-de-Menezes","year":"2018","journal-title":"Health Prev Dent"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2.3.479","article-title":"Amifostine: chemotherapeutic and radiotherapeutic protective effects","volume":"2","author":"Santini","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"B48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00520-023-07718-2","article-title":"Efficacy of regional cooling\u2009+\u2009oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin","volume":"31","author":"Nara","year":"2023","journal-title":"Support Care Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010074","article-title":"Interventions for the prevention of oral mucositis in patients receiving cancer treatment: evidence from randomized controlled trials","volume":"30","author":"Colella","year":"2023","journal-title":"Curr Onco"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1564681\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:14:09Z","timestamp":1747872849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1564681\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":49,"alternative-id":["10.3389\/fonc.2025.1564681"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1564681","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"article-number":"1564681"}}